Joy Global and Biogen climb; Intel and Union Pacific slide

The chipmaker reported a sharp drop in quarterly profit and its sales fell short of analyst projections.

The company posted disappointing revenue as it sells some stores and tries to shake up its menu.

The drugmaker announced strong quarterly results backed by sales of some of its newest multiple sclerosis and hemophilia treatments.